Status:
COMPLETED
Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Bristol-Myers Squibb
GlaxoSmithKline
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to evaluate virological efficacy and safety of two double protease inhibitor regimens: atazanavir/fosamprenavir/ritonavir 300 mg once daily/ 700/100 mg twice daily, versus...
Detailed Description
The purpose of this randomized, open-label study is to evaluate virological efficacy and safety of two double protease inhibitor regimens: atazanavir/fosamprenavir/ritonavir 300 mg once daily/ 700/100...
Eligibility Criteria
Inclusion
- Protease inhibitor naive patients
- Wild type genotype
- CD4 greater than 200/mm3
- Viral load between 10,000 copies/ml and 750,000 copies/ml
- Signed informed consent
Exclusion
- Pregnancy; breast feeding
- Antiretroviral (ARV) pretreated patients
- Hyperlipidemic treatment
- Evolutive disease
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00122603
Start Date
December 1 2005
End Date
August 1 2007
Last Update
December 22 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service des Maladies infectieuses et tropicales Hopital Bichat Claude Bernard
Paris, France, 75018